Efficacy of the Hemoperfusion Therapy in Patients with Severe COVID-19-Associated Pneumonia: An Experience from Single-center Observational Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20210627002

Enrollment

Registered

2021-06-27

Start date

2021-04-13

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe COVID-19-associated pneumonia with or without hemoperfusion therapy Hemoperfusion, adsorption therapy, COVID-19, Pneumonia, Acute respiratory distress syndrome, Critical care, SARS-CoV2, cytokine storm, blood purification

Interventions

Severe COVID-19-associated pneumonia with hemoperfusion therapy,Severe COVID-19-associated pneumonia without hemoperfusion therapy

Treatment,Treatment

Hemoperfusion,No hemoperfusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >18 years, 2. Severe COVID-19-associated pneumonia with or without hemoperfusion therapy, 3. Admitted in Chiang Mai University Hospital, Chiang Mai, Thailand

Exclusion criteria

Exclusion criteria: No

Design outcomes

Primary

Measure	Time frame
Cytokine levels Before and after hemoperfusion ELISA kit	—

Secondary

Measure	Time frame
SOFA score Before and after hemoperfusion Lab parameter	—

Countries

Thailand

Contacts

Public ContactPRIT KUSIRISIN

Chiang Mai University

jingprit@hotmail.com0897574028

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026